背景:液体活检,包括循环肿瘤细胞(CTC)的检测,已成为癌症诊断和监测的有前途的工具。然而,由于缺乏表型表征,CTC在鼻咽癌(NPC)中的预后价值尚不清楚.切除修复交叉互补组1(ERCC1)和CTC上皮-间质转化(EMT)的表达与治疗效果相关。在这项研究中,我们旨在评估NPC治疗前CTC及其EMT亚型ERCC1表达的预后意义.
方法:我们回顾性分析了在2018年11月至2021年11月期间接受CanPatrol™CTC检测的108例新诊断的局部晚期NPC患者。对CTC进行计数并分类为上皮,上皮-间质杂种,和间充质亚型。ERCC1表达分为阴性组和阳性组。分析临床特征和生存结果。
结果:CTC阳性率为92.6%(100/108),ERCC1阳性率为74%(74/100)。对亚型的进一步分析显示,间充质CTC上的ERCC1阳性与晚期N期相关(P=0.01)。ERCC1阳性表达与总体生存率(OS;P=0.039)和无病生存率(DFS;P=0.035)相关。对亚型的进一步分析表明,间充质型CTC上的ERCC1阳性与不良OS(P=0.012)和无转移生存期(MFS;P=0.001)相关。
结论:我们的研究结果表明,ERCC1在CTC上的表达可能是鼻咽癌患者的一个新的预后指标。评估CTC亚型可能成为个性化和精确治疗的辅助工具。
背景液体活检,包括循环肿瘤细胞(CTC)的检测,已成为癌症诊断和监测的有前途的工具。然而,由于缺乏表型表征,CTC在鼻咽癌(NPC)中的预后价值尚不清楚.切除修复交叉互补组1(ERCC1)和CTC上皮-间质转化(EMT)的表达与治疗效果相关。在这项研究中,我们旨在评估NPC治疗前CTC及其EMT亚型ERCC1表达的预后意义.方法回顾性分析2018年11月至2021年11月接受CanPatrol™CTC检测的108例新诊断的局部晚期NPC患者。对CTC进行计数并分类为上皮,上皮-间质杂种,和间充质亚型。ERCC1表达分为阴性组和阳性组。分析临床特征和生存结果。结果CTCs阳性率为92.6%(100/108),ERCC1阳性率为74%(74/100)。对亚型的进一步分析显示,间充质CTC上的ERCC1阳性与晚期N期相关(P=0.01)。ERCC1阳性表达与总体生存率(OS;P=0.039)和无病生存率(DFS;P=0.035)相关。对亚型的进一步分析表明,间充质型CTC上的ERCC1阳性与不良OS(P=0.012)和无转移生存期(MFS;P=0.001)相关。结论我们的研究结果表明,ERCC1在CTC上的表达可能是NPC患者预后的新指标。评估CTC亚型可能成为个性化和精确治疗的辅助工具。
BACKGROUND: Liquid biopsy, including the detection of circulating tumor cells (CTCs), has emerged as a promising tool for cancer diagnosis and monitoring. However, the prognostic value of CTCs in nasopharyngeal carcinoma (NPC) remains unclear due to the lack of phenotypic characterization. The expression of Excision Repair Cross-Complementation Group 1 (ERCC1) and CTCs epithelial-mesenchymal transition (EMT) have been associated with treatment efficacy. In this study, we aimed to evaluate the prognostic significance of ERCC1 expression on CTCs and their EMT subtypes before treatment in NPC.
METHODS: We retrospectively analyzed 108 newly diagnosed locally advanced NPC patients who underwent CanPatrol™ CTC testing between November 2018 and November 2021. CTCs were counted and classified into epithelial, epithelial-mesenchymal hybrid, and mesenchymal subtypes. ERCC1 expression was divided into negative and positive groups. Clinical features and survival outcomes were analyzed.
RESULTS: The positive rate of CTCs was 92.6% (100/108), with an ERCC1 positivity rate of 74% (74/100). Further analysis of the subtypes showed that positive ERCC1 on mesenchymal CTCs was associated with a later N stage (P = .01). Positive ERCC1 expression was associated with poor overall survival (OS; P = .039) and disease-free survival (DFS; P = .035). Further analysis of subtypes showed that the positive ERCC1 on mesenchymal-type CTCs was associated with poor OS (P = .012) and metastasis-free survival (MFS; P = .001).
CONCLUSIONS: Our findings suggest that ERCC1 expression on CTCs may serve as a new prognostic marker for NPC patients. Evaluating CTCs subtypes may become an auxiliary tool for personalized and precise treatment.
BackgroundLiquid biopsy, including the detection of circulating tumor cells (CTCs), has emerged as a promising tool for cancer diagnosis and monitoring. However, the prognostic value of CTCs in nasopharyngeal carcinoma (NPC) remains unclear due to the lack of phenotypic characterization. The expression of Excision Repair Cross-Complementation Group 1 (ERCC1) and CTCs epithelial-mesenchymal transition (EMT) have been associated with treatment efficacy. In this study, we aimed to evaluate the prognostic significance of ERCC1 expression on CTCs and their EMT subtypes before treatment in NPC.MethodsWe retrospectively analyzed 108 newly diagnosed locally advanced NPC patients who underwent CanPatrol™ CTC testing between November 2018 and November 2021. CTCs were counted and classified into epithelial, epithelial-mesenchymal hybrid, and mesenchymal subtypes. ERCC1 expression was divided into negative and positive groups. Clinical features and survival outcomes were analyzed.ResultsThe positive rate of CTCs was 92.6% (100/108), with an ERCC1 positivity rate of 74% (74/100). Further analysis of the subtypes showed that positive ERCC1 on mesenchymal CTCs was associated with a later N stage (P = .01). Positive ERCC1 expression was associated with poor overall survival (OS; P = .039) and disease-free survival (DFS; P = .035). Further analysis of subtypes showed that the positive ERCC1 on mesenchymal-type CTCs was associated with poor OS (P = .012) and metastasis-free survival (MFS; P = .001).ConclusionOur findings suggest that ERCC1 expression on CTCs may serve as a new prognostic marker for NPC patients. Evaluating CTCs subtypes may become an auxiliary tool for personalized and precise treatment.